HepQuant to Present at Biotech Showcase™ 2020
San Francisco Event to be held January 13–15th
DENVER (Jan. 10, 2020) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15th, during the most important week in healthcare at the Hilton San Francisco Union Square.
Date: Tuesday, January 14th, 2020
Time: 4:30 p.m.
Track: Franciscan C – Ballroom level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Senior executives at HepQuant will be available for one-on-one meetings with attendees at the Biotech Showcase. HepQuant’s senior team will also be attending the 38th Annual J.P. Morgan Conference and available to meet from Sunday, January 12th – Thursday, January 16th.
HepQuant is bringing a disruptive new gold standard to market, “a liver function test” to address the Chronic Liver Disease and NASH markets. Research studies have encompassed over 1,600 tests in more than 700 subjects across the spectrum of Chronic Liver Disease. The company is currently conducting a Pivotal Study related to varices management with plans for a PMA submission and US Food and Drug Administration (FDA) review 2020 – 2021. In addition, six major pharmaceutical companies are using HepQuant tests in current clinical trials. FDA, key opinion leaders and payers have encouraged the use of liver function testing in drug development and clinical trials. HepQuant has 35 patents awarded or pending. HepQuant currently is engaging commercial partners in discussions to accelerate commercialization.
“HepQuant is conducting and enrolling our pivotal trial to support a potential market approval in varices management. In addition, many NASH trials have struggled due to lack of quality endpoints. HepQuant believes its tests offer advantages in screening for NASH and monitoring NASH treatments. The need for a genuine next generation global liver function test is more evident than ever before,” said Dr. Greg Everson, CEO and Chief Medical Officer at HepQuant. “We hope to engage partners at Biotech Showcase and J.P. Morgan Conference to accelerate our technology towards the market in the near future.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that HepQuant, LLC will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
Headquartered in Greenwood Village, Colorado, HepQuant, LLC, is a privately-held, early-stage combination drug and in-vitro diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
BUSINESS & INVESTOR CONTACT:
Bradley C. Everson | Chief Business Development Officer | Ph: (303) 923 – 2150 | [email protected]
Sean Bundy | Director of Regulatory and Quality Affairs | [email protected]